Locations:
Search
Case-control study yields evidence of epigenetic aging in pediatric-onset MS
Novel insights from a postmortem study combining imaging, pathology and clinical perspectives
Long-awaited efficacy against disability progression in nonrelapsing SPMS appears to be at hand
Extension of DELIVER-MS trial will clarify long-term clinical effects of dueling treatment philosophies
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
BTK inhibitor tolebrutinib shows positive results in phase 3 HERCULES trial
No effect on symptom severity or disability, and low prevalence of long COVID
Using multidisciplinary care to address mood changes, mitigate daily stressors
MRI classifier identifies a subset of patients with disease marked by cortical atrophy, not demyelination
A co-author explains some of the key McDonald criteria revisions
The BTK inhibitor tolebrutinib meets its primary endpoint in phase 3 HERCULES trial
Advertisement
Advertisement